funding – EJP RD – European Joint Programme on Rare Diseases https://www.ejprarediseases.org Thu, 10 Nov 2022 13:15:31 +0000 en-GB hourly 1 https://wordpress.org/?v=5.9.9 https://www.ejprarediseases.org/wp-content/uploads/2020/11/cropped-index-32x32.png funding – EJP RD – European Joint Programme on Rare Diseases https://www.ejprarediseases.org 32 32 The “Joint Transnational Call” back on December 12th https://www.ejprarediseases.org/the-joint-transnational-call-back-on-december-12th/?utm_source=rss&utm_medium=rss&utm_campaign=the-joint-transnational-call-back-on-december-12th Thu, 10 Nov 2022 13:10:59 +0000 https://www.ejprarediseases.org/?p=14216 The EJP RD Joint Transnational Call, a funding opportunity for research projects, will be launched on December 12th.

The aim of the funding opportunity is to enable scientists in different countries to build an effective collaboration on a common interdisciplinary research project based on complementarities and sharing of expertise, with expected impact to use the results in the future for benefit of patients

TopicNatural History Studies addressing unmet needs in Rare Diseases

Don’t miss the information webinar will be held on December 15th for potential applicants.

Timetable, contact, and more information here: https://www.ejprarediseases.org/joint-transnational-call-2023/

]]>
Innovative Health Initiative (IHI) announces Kick-off and brokerage event https://www.ejprarediseases.org/innovative-health-initiative-ihi-announces-kick-off-and-brokerage-event/?utm_source=rss&utm_medium=rss&utm_campaign=innovative-health-initiative-ihi-announces-kick-off-and-brokerage-event Wed, 18 May 2022 15:36:52 +0000 https://www.ejprarediseases.org/?p=12541 The Innovative Health Initiative (IHI), a European Union public-private partnership funding health research and innovation, is organising a kick-off and brokerage event that will provide pertinent information on upcoming IHI call topics and processes and facilitate network building through face-to-face and virtual meetings as well as pitching sessions.

This event, which is targeted towards small and medium-sized enterprises, patient organisations, regulatory authorities, academic teams, industry, hospitals and other organisations with an interest in IHI projects, will take place in Brussels, Belgium and online on June 14th from 09.00 to 17.00 CET.

  • Info session: The first part of the morning is a classic info session. It will cover the topics of the first calls, the call conditions and rules for participation, and opportunities for SMEs. The session includes time for questions.
  • Networking: To submit a proposal for an IHI call, you need to be part of a consortium. The second half of the morning and the afternoon are dedicated to networking via one-on-one brokerage meetings and pitching sessions.

Participation in the event is free but registration is mandatory.

For more information and registration: https://ihi-calls-2022.b2match.io/

]]>
Chan Zuckerberg Initiative hosts Networking Expo for Patient-Partnered Collaborations (PPC) for Rare Disease https://www.ejprarediseases.org/chan-zuckerberg-initiative-hosts-networking-expo-for-patient-partnered-collaborations-ppc-for-rare-disease/?utm_source=rss&utm_medium=rss&utm_campaign=chan-zuckerberg-initiative-hosts-networking-expo-for-patient-partnered-collaborations-ppc-for-rare-disease Wed, 23 Mar 2022 16:53:38 +0000 https://www.ejprarediseases.org/?p=11722 Earlier this year, the Chan Zuckerberg Initiative (CZI) launched two Requests for Applications (RFA) for grant opportunities that will fund collaborative teams bringing together patient-led rare disease organizations and research teams for 4-year research projects aimed at advancing our understanding of the fundamental science of rare diseases.

The Networking Expo is a two-day ideation and matchmaking workshop specifically designed as an opportunity for researchers and patient-advocates/organizations who are looking to develop a new collaboration to connect around potential projects for the Patient-Partnered Collaborations (PPC) for Rare Neurodegenerative Disease RFA.

The virtual event will take place over two days on April 20th – 21st.

Space is limited for these sessions and participants will be selected through a brief application process. Registration for the Networking Expo is open until April 8th.

For more information: https://apply.hub.ki/czi-patient-partnered-collaborations/ 

]]>
EJP RD – ERN Research Training Workshops funding opportunity OPEN until April 25th! https://www.ejprarediseases.org/ejp-rd-ern-research-training-workshops-funding-opportunity-open-until-april-25th/?utm_source=rss&utm_medium=rss&utm_campaign=ejp-rd-ern-research-training-workshops-funding-opportunity-open-until-april-25th Fri, 18 Mar 2022 16:10:50 +0000 https://www.ejprarediseases.org/?p=11636

The ERN Research Training Workshops funding opportunity is now open for applications until April 25th. The goal of the workshops is to train researchers and clinicians affiliated to ERN- Full  Members or – Affiliated Partners in relevant topics on research in rare diseases. Training themes may include innovative research methodologies, diagnostic research topics, interdisciplinary treatment approaches, such as gene therapy and transplantation, etc. Moreover, the workshops will be aiming to provide a cross-ERN added value.  

The workshops will be delivered as two-day events. The costs for the workshop organization will be covered up to a limit of €25,000 (venue, administrative, audio-visual and IT facilities essential for the workshop, catering, travel and accommodation expenses of workshops participants and invited speakers, if envisaged). 

The workshops selected for funding will be attended only by individuals affiliated to ERN institutions. Participants will be selected by the coordinator of the ERN managing institution and the workshop organizer based on pre-defined criteria. 

Organizer’s profile: 

The applicant submitting workshop topics must fulfil one of the following conditions: 

  • Affiliated to any EJP RD beneficiary institution
  • Affiliated to an ERN Full Member
  • Affiliated to an ERN Affiliated Partner institution at the time when the application is submitted, as well as during the period of the execution of the workshop. 

Application and more information here.

]]>
EIC funding call for RNA-based therapies and diagnostics for rare genetic diseases https://www.ejprarediseases.org/eic-funding-call-for-rna-based-therapies-and-diagnostics-for-rare-genetic-diseases/?utm_source=rss&utm_medium=rss&utm_campaign=eic-funding-call-for-rna-based-therapies-and-diagnostics-for-rare-genetic-diseases Mon, 21 Feb 2022 17:44:18 +0000 https://www.ejprarediseases.org/?p=11202 The European Commission (EC) has adopted the 2022 work programme of the European Innovation Council (EIC), opening funding opportunities worth over €1.7 billion in 2022 for breakthrough innovators to scale up and create new markets. This includes €60.5 million to tackle three Transition Challenges, notably one on the development of RNA-based therapies and diagnostics for complex or rare genetic diseases.

The EIC Transition 2022 (HORIZON-EIC-2022-TRANSITION-01) call, which has a planned opening date of March 1st, is intended to meet the following specific objectives:

  1. Advance, beyond the state-of-the-art, RNA delivery methods, including robust mRNA formulations, that would enable effective and safe delivery of mRNA into the cells;
  2. Design, develop and preclinical validate of novel miRNAs (miRNA lncRNA, tRNA or siRNA-based) therapies for complex or rare genetic diseases;
  3. Develop and validate novel RNA-based diagnostics and RNA-based predictive biomarkers that would allow for early and more accurate diagnosis and for favourable or non- post-treatment prognosis, respectively.

The starting point in the project should be a preliminary technology or protocol of an RNA-based therapy for complex or rare genetic diseases with unmet medical needs that demonstrates, in a lab or preclinical context, the essential features that underpin the disruptive nature of the innovation. The endpoint in the project should be a completely functional version of the technology suitable for clinical validation, supported by a sound and implementable commercialisation/exploitation strategy.

The funding call has the following deadlines: May 4th and September 28th.

For more information: https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/horizon-eic-2022-transitionchallenges-03

]]>
Scientify Research publishes curated list of rare disease grants and funding opportunities https://www.ejprarediseases.org/scientify-research-publishes-curated-list-of-rare-disease-grants-and-funding-opportunities/?utm_source=rss&utm_medium=rss&utm_campaign=scientify-research-publishes-curated-list-of-rare-disease-grants-and-funding-opportunities Mon, 14 Feb 2022 17:35:08 +0000 https://www.ejprarediseases.org/?p=11139 Scientify Research, a Swedish company providing an open, curated and structured research funding database that focuses on aggregating information on funding opportunities across several research areas, has published a curated list of grants and funding opportunities available in the field of rare diseases.

The website also collates information about research funders, and users are allowed to submit new grant and funding opportunity information for eventual inclusion in the list.

For more information and to consult the list: https://www.scientifyresearch.org/all-rare-disease-funding-opportunities/

]]>
Chan Zuckerberg Initiative announces two patient-partnered Requests for Application (RFA) with rare disease focus https://www.ejprarediseases.org/chan-zuckerberg-initiative-announces-two-patient-partnered-requests-for-application-rfa-with-rare-disease-focus/?utm_source=rss&utm_medium=rss&utm_campaign=chan-zuckerberg-initiative-announces-two-patient-partnered-requests-for-application-rfa-with-rare-disease-focus Fri, 11 Feb 2022 13:29:10 +0000 https://www.ejprarediseases.org/?p=11117 The Chan Zuckerberg Initiative (CZI) is inviting applications from collaborative teams bringing together patient-led rare disease organisations and research teams for 4-year research projects aimed at advancing understanding of the fundamental science of rare diseases across two requests for applications (RFAs)

  • The Patient-Partnered Collaborations for Single-Cell Analysis of Rare Inflammatory Pediatric Disease RFA aims to support the application of single-cell biology methods to rare inflammatory pediatric diseases in order to clarify cellular mechanisms of disease, improve understanding of disease heterogeneity, identify biomarkers, and improve diagnosis. Patient organizations are expected to be active collaborators on this research opportunity and full partners in the development of the grant application.

For more information about these RFAs, an informational webinar is being organised on February 16th from 18.00 – 19.00 CET.

To register for the webinar: https://app.smartsheet.com/b/form/c3778f11ace64be3a2e0cec66b11ea4f

The deadline for submitting applications is May 24th.

For more information and to complete the RFAs: https://apply.chanzuckerberg.com/

]]>
Innovative Health Initiative (IHI) announces upcoming funding opportunities for 2022 https://www.ejprarediseases.org/innovative-health-initiative-ihi-announces-upcoming-funding-opportunities-for-2022/?utm_source=rss&utm_medium=rss&utm_campaign=innovative-health-initiative-ihi-announces-upcoming-funding-opportunities-for-2022 Wed, 19 Jan 2022 14:56:03 +0000 https://www.ejprarediseases.org/?p=10762 The Innovative Health Initiative (IHI), a European Union public-private partnership funding health research and innovation, has published draft information on upcoming funding opportunities in 2022 in order to give potential applicants additional time to find or build a consortium and prepare a strong proposal.

The first call for proposals will be launched in the first half of 2022. The following draft themes could be included in the future calls:

Single stage calls

  • Innovative patient-facing care pathways for patients with neurodegenerative diseases and comorbidities
  • Next generation imaging and image-guided diagnosis and therapy for cancer
  • Precision oncology: Innovative patient-centric, multi-modal therapies against cancer
  • Access and integration of heterogeneous health data for improved health care in diseases areas of high unmet public health need.

Two stage calls

  • New tools for prediction, prevention and monitoring of cardio-metabolic diseases including secondary manifestations to enable timely intervention
  • Strengthening EU clinical development excellence and innovation attractiveness: Harmonised methodology to promote the uptake of early feasibility studies (EFS)

Please check the IHI website and social media for regular updates related to the upcoming calls.

For more information (including summaries of the draft themes): https://www.ihi.europa.eu/apply-funding/future-opportunities

]]>
FDA announces 2022 grant funding opportunity for rare disease research https://www.ejprarediseases.org/fda-announces-2022-grant-funding-opportunity-for-rare-disease-research/?utm_source=rss&utm_medium=rss&utm_campaign=fda-announces-2022-grant-funding-opportunity-for-rare-disease-research Fri, 07 Jan 2022 15:36:30 +0000 https://www.ejprarediseases.org/?p=10710 The Food and Drug Administration’s (FDA) Office of Orphan Products Development (OOPD) is pleased to announce availability of funds for to support natural history studies for rare diseases and conditions. These studies are intended to provide acceptable data to the FDA that will substantially contribute to the approval of new products, or new indications for already marketed products. In the FDA OOPD Orphan Products Grants Program, products for rare diseases and conditions (orphan products) are defined as drugs, biologics, medical devices, and medical foods indicated to treat or diagnose a rare disease or condition with a prevalence of fewer than 200,000 people in the United States.  

Apply here: Efficient and Innovative Natural History Studies Addressing Unmet Needs in Rare Diseases (R01)

  • Receipt Date: February 15, 2022 and February 13, 2024
  • FOA Number: RFA-FD-22-001

Purpose: To support efficient and innovative natural history studies that advance medical product development in rare diseases/conditions with unmet needs. 

Focus: Natural history studies with high quality and interpretable data elements

Contact: Katherine Needleman, Director, Orphan Products Grants Program

More information here

]]>
EJP RD announces opening of Joint Transnational Call (JTC) 2022 https://www.ejprarediseases.org/ejp-rd-announces-opening-of-joint-transnational-call-jtc-2022/?utm_source=rss&utm_medium=rss&utm_campaign=ejp-rd-announces-opening-of-joint-transnational-call-jtc-2022 Tue, 14 Dec 2021 11:10:56 +0000 https://www.ejprarediseases.org/?p=10361 We are glad to announce today (December 14th 2021) the official launch of the Joint Transnational Call 2022, a funding opportunity for research projects on the development of new analytic tools and pathways to accelerate diagnosis and facilitate diagnostic monitoring of rare diseases.

The aim of the funding opportunity is to enable scientists in different countries to build an effective collaboration on a common interdisciplinary research project based on complementarities and sharing of expertise, with expected impact to use the results in the future for benefit of patients.

TopicDevelopment of new analytic tools and pathways to accelerate diagnosis and facilitate diagnostic monitoring of rare diseases

The EJP RD Joint Transnational Call 2022 Information Webinar will provide you general information on the call (scientific goals, administrative aspects) and will answer your question on this call. The webinar will take place online on December 16th 2021, from 14.00 – 15.30 CET. Registration is mandatory for the webinar: https://forms.office.com/r/P7cYnbLLYG.

JTC2022 timetable, contact, and more information here: https://www.ejprarediseases.org/jtc2022/

]]>